Equine herpesvirus 1 (EHV-1) strain Ab4 gene 71 is predicted to encode a primary product with a M r of 80.1K. We have previously constructed a deletion/laeZ insertion mutant, ED71, and demonstrated that gene 71 is dispensable for growth of virus in cell culture. We have now constructed a gene 71 revertant, Re71. To identify and characterize the product of gene 71, we produced a specific antiserum, anti-71, against a fl-galactosidase fusion protein containing the carboxy terminus of the gene 71 polypeptide. Using the anti-71 serum, mutant ED71 and the revertant Re71, we have demonstrated that gene 71 encodes a 192K polypeptide. Experiments with glycosylation inhibitors revealed that the protein product of gene 71 is N-glycosylated and heavily Oglycosylated. When the 192K polypeptide is synthesized in the presence of monensin, the M r of the polypeptide is reduced to 80K, the predicted unmodified M r of the gene 71 polypeptide. The gene 71 product is found in virions and L particles in a fully processed form that runs as a diffuse band in electrophoresis, with a M r in excess of 200K. Immunofluorescence and virion surface labelling experiments showed that the polypeptide product of gene 71 is located on cellular membranes and the virion envelope. A time course of infection confirmed that gene 71 is regulated as a leaky late gene in infected cells. Finally, using wild-type EHV-1 Ab4, mutant ED71, revertant Re71 and two antibodies (P19 against EHV-1 glycoprotein gp300, and anti-71) we conclusively demonstrated that gene 71 encodes gp300. This contradicts published results with P19 alone, which indicated gp300 was the product of EHV-1 gene 28.
Introduction
Equine herpesvirus 1 (EHV-1), a member of the subfamily Alphaherpesvirinae, is a significant viral pathogen of horses, causing a variety of clinical problems including respiratory disease, abortion and neurological disorders (Bryans & Allen, 1989 ). The EHV-1 genome is a linear dsDNA molecule of approximately 150 kbp in size that consists of two covalently linked components, the long and short regions (Whalley et al,, 1981) . The complete DNA sequence of strain Ab4, a pathogenic U.K. isolate of EHV-1, has recently been determined (Telford et aI., 1992) . The genome is 150223 bp in size and contains 76 distinct open reading frames (ORFs). At least 10 of these ORFs have been predicted to encode membrane glycoproteins. To date up to 13 glycoproteins have been found in EHV-1 virions, ranging in M r from 24000 to 260000 (Turtinen & Allen, 1982; Meredith et al., 1989) . Some have been characterized and mapped to ORFs. Herpesvirus glycoproteins play an important role in essential viral functions such as absorption, penetration and egress. Consequently they play a significant role in viral pathogenesis (Spear, 1993) . They are also the main targets of neutralizing antibodies.
Gene 71 is located in the short unique region of the EHV-1 genome and is predicted to encode a 797 amino acid polypeptide. The gene corresponds in position to herpes simplex virus type 1 (HSV-1) gene US5, which encodes a potential glycoprotein, gJ, that also contains a single putative N-linked glycosylation site (McGeoch et al., 1985) . However no similarity was detected between the EHV-1 and HSV-1 amino acid sequences (Telford et al., 1992) . The predicted amino acid sequence of EHV-1 gene 71 contains a single putative N-linked glycosylation site and an extensive region encoding a high proportion of serine and threonine residues, which is likely to be heavily O-glycosylated. Two equivalent ORFs, EUS4 and ORF1, have been identified in the Ky A and D strains respectively of EHV-1 (Audonnet et al., 1990; Colle et al., 1992) . These encode 383 amino acid polypeptides with a predicted M r of 40K and have the same amino and carboxy termini as the gene 71 protein, but they differ in having an internal deletion and two potentrial N-linked glycosylation sites. Their amino acid sequence is also rich in serine and threonine residues.
We have previously demonstrated that gene 71 of EHV-1 Ab4 is non-essential for virus growth in cell culture by the construction of a viable mutant, ED71, in which the gene 71 ORF has been deleted (Sun & Brown, 1994) . In this paper, we have identified and characterized the protein product of gene 71 using an antiserum raised against its carboxy terminus (amino acids 465 to 797). The specificity of this antiserum was confirmed using the deletion/insertion mutant ED71 and its revertant Re71.
Methods
Cells and virus. Baby hamster kidney clone 13 cells [BHK-21 (C13); Macpherson & Stoker, 1962] were propagated as previously described (Brown et al., 1973) . EHV-1 strain Ab4p (kindly supplied by Dr E. A. R. Telford) was the wild-type virus strain used in this study. Stock preparation of the virus at passage 13 was made by low multiplicity passage in equine dermal NBL-6 cells maintained in MEM with 1% fetal calf serum. The construction of mutant ED71, in which the gene 71 ORF was removed and substituted with lacZ has been previously described (Sun & Brown, 1994) .
Construction of a revertant virus of mutant ED71.
To isolate a revertant of ED71, the cloned 5.8 kbp BamHI EcoRl (positions 126517 to 132305) fragment in pU71 (Sun & Brown, 1994) was cotransfected as described by Stow & Wilkie (1976) with intact viral DNA of mutant ED71. Individual plaques lacking lacZ were isolated in medium containing X-Gal (0.05 mg/ml) and their DNA analysed for a wild-type profile (Sun & Brown, 1994) . Revertant viruses were plaque-purified a further three times before a virus stock was prepared.
Plasmids. pUEH71, which expresses amino acids 454 to 797 of gene 71 fused to the carboxy terminus offl-galactosidase in pUR278 (RiJther & Mtiller-Hill, 1983 ) was constructed by inserting a HindIII fragment (130487 to 131594) into the pUR278 HindlII site at the 3' end of the lacZ gene.
Preparation of a bacterial fusion protein and rabbit antisera against the gene 71 product. The fl-galactosidase fusion protein was prepared by the method of Harlow & Lane (1988) . Two New Zealand white rabbits were each initially injected subcutaneously with 0-6 mg of total protein dissolved in 0-25 ml of water and emulsified with an equal volume of Freund's complete adjuvant. Each rabbit was boosted on days 14, 30, 60 and 90 with an emulsion of 0.2 mg of fusion protein dissolved in 0.25 ml of water plus an equal volume of Freund's incomplete adjuvant. Final antisera were collected on day 100.
Preparation of radiolabelled cell extracts. Confluent BHK-21 (C 13) cell monolayers in 35 mm Petri dishes were infected with virus at 20 p.f.u./cell in Eagle's MEM containing 2 % calf serum. Infected cells were labelled from 5 h to 20 h post-infection (p.i.) with 50 gCi/ml of [35S]methionine (Amersham; > 1000 Ci/mmol) in medium containing one-fifth the normal concentration of methionine, or either 2.5 laCi/ml of [14C]glucosamine (50 mCi/mmol) or 3 laCi/ml of [~H]mannose (10 to 20 Ci/mmol) in medium containing one-tenth the normal level of glucose.
Immunoprecipitation. Infected cell polypeptides were harvested and immunoprecipitations carried out essentially as described by MacLean et al. (1992) except that 200 gl of the supernatant was incubated with 20 gl of antiserum overnight at 4 °C and then transferred to ice for a further 2 h in the presence of 60 gl of a 50 % (v/v) suspension of Protein A-Sepharose.
Surface labelling of virion proteins. EHV-1 virion proteins were labelled in vitro by enzymatic labelling specific for exposed carbohydrate residues on the virion envelope surface (Wallenfels, 1979) . Briefly, the reaction mixture containing (in a total volume of 460/al) 0"25 M-Tris-HC1 pH 7-4, 400/ag of purified virions, 2 gCi UDP-[14C]galactose (270 mCi/mmol), 0-28 units of galactosyl transferase and 0.02M-MnC12 was incubated with shaking for 1 h at 37 °C, followed by 5 min at 0 °C. The labelled virions were washed by centrifugation in 10 mM-Tris-HC1 pH 7.5 and 1 mM-EDTA to remove unincorporated UDP-[14C]galactose.
Immunoblotting. Confluent BHK-21 (C13) cell monolayers were infected at a multiplicity of 20 p.f.n./cell and maintained in medium containing 2% calf serum. To inhibit viral DNA synthesis, cells were maintained from 1 h before and then throughout infection in medium containing 300 lag/ml phosphonoaeetic acid (PAA; Sigma). Infected cell polypeptides were harvested up to 24 h p.i. in 0.15 ml of extraction buffer per 106 cells and immunoblotting was carried out as described by Frame et al. (1987) . Anti-71 serum was diluted 100-fold. Monoclonal antibody (MAb) P19 against EHV-1 gp300 has been previously described (Whittaker et al., 1992) and was kindly supplied to Dr D. Meredith. The reactivities on Western blots of MAb 6898 and rabbit antiserum 14327, used to detect expression of UL42 and US11, were characterized respectively by Parris et al. (1988) and MacLean et al. (1987) .
Treatment with glycosylation inhibitors. Confluent monolayers of BHK-21 (C13) cells were infected with virus at 20 p,f.u./cell or mockinfected. The cells were treated with 2 lag/ml tunicamycin (Sigma) or 1 gM-monensin (Sigma) from the end of the absorption period (1 h) until 20 h p.i.
Treatment with glycosidases
(i) N-glycanase. Purified EHV-1 virions (10 gl) were incubated with 10 lal of 1% (v/v) Triton X-100 at 0 °C for 10 rain and centrifuged at 10000g for 10 rain. The supernatant was treated with 15 lal of 0-2 Msodium phosphate buffer pH 8.6, 3 gl of 100 mM-l,10-phenanthroline and 10 units/ml N-glyeosidase [peptide-N-4(N-acetyl-fl-glucosaminyl) asparagine amidase; Genzyme] and incubated at 37 °C for 6 h.
(ii) Neuraminidase. Purified EHV-1 virions were treated with Nglycanase as above and adjusted to pH 5 with 0.1 M-citric acid. Next 0.2 units of neuraminidase (acetylneuraminyl hydrolase; Sigma) was added and incubated at 37 °C for 4 h.
(iii) Exoglycanidases. Purified EHV-I virions were digested with Nglycanase followed by neuraminidase as above, fl-N-acetylhexosaminidase (2-acetamido-2-deoxy-fl-B-glucoside acetamidodeoxyglucohydrolase; Sigma; 0.01 unit, 0.01 unit of L-fucoside fusohydrolase (Sigma) and 0.01 unit of fl-galactosidase (fl-D-galactoside galactohydrolase; Boehringer Mannheim) were added and incubated at 25 °C for 4 h.
Subcellularfractionation. Subcellular fractionation was based on the method described by Bryant &Ratner (1990) as modified by MacLean et al. (1992) . Infected cells in buffer adjusted to 150 mM-NaC1 were separated into supernatant (cytosol) and total membrane fractions. A sample of the total membrane fraction was then adjusted to 1 M-NaC1 and separated into a supernatant fraction containing those proteins that bound only at low ionic strength and a pellet fraction containing proteins that bound to membranes at high ionic strength.
Purification of virus particles. The procedure used was essentially that described by Szil~igyi & Cunningham (1991) . Briefly, monolayers of BHK-21 (C13) cells in 80 oz roller bottles were infected with 1000 p.f.u. of EHV-1 strain Ab4 and incubated until c.p.e, was complete. Supernatant virus was separated into two fractions, a virion preparation and an L particle preparation, which consisted of nucleocapsidfree tegument~nvelope structures.
Immunofluorescence. For detection of cell surface antigens, cells infected with EHV-1 Ab4 for 16 h were washed twice in PBS and fixed in PBS containing 4 % formaldehyde at room temperature for 10 rain 
Regulation of expression of the gene 71 protein product
To study gene regulation, a time course analysis of gene 71 expression was carried out. Cells were harvested at various times after infection and polypeptides were separated by 8 % SDS-PAGE, transferred to a nitrocellulose membrane and probed with anti-71 serum. The 192K protein was first detected at 8 h p.i. ; the amount increased until about 12 h and remained constant up to 24 h (Fig. 3) examined in the presence of 300 gg/ml PAA. At this concentration of PAA, virus D N A replication is reduced to undetectable levels ( < 5 % of the untreated control) in cells infected with HSV-1 strain 17 + (Johnson et al., 1986) . Similarly, we have demonstrated that PAA inhibits EHV-1 (Ab4) DNA synthesis to less than 5 % of controls. Infected cells were harvested at 0, 6, 12 and 24 h postabsorption. The 192K M r polypeptide was first detected at 8 h after adsorption both in the absence and presence of PAA, but the expression of gene 71 was reduced significantly in the presence of PAA (Fig. 3) . In cells infected with HSV-1 17 +, no synthesis of the true late gene US11 (Johnson et al., 1986) could be detected at any time after infection in the presence of PAA (data not shown), whereas the delayed early gene, UL42, (Goodrich et al., 1989) was clearly detectable by 6 h p.i. and only slightly inhibited by PAA (data not shown). We therefore concluded that gene 71 is regulated as a leaky late gene in EHV-l-infected cells.
Location of the gene 71-encoded potypeptide within infected cells
To determine the cellular distribution of the gene 71 polypeptide, infected cells were fractionated into a soluble cytosol fraction and a membrane-containing fraction. The 192K protein was detected in the membrane-associated fraction by immunoblotting and was not released by treatment with 1 M-NaC1, indicating that it is bound with relatively high affinity to cellular membranes (Fig. 4) .
Location of the gene 71 polypeptide within the virus particle
EHV-1 virus preparations consist of virions and L particles, which are essentially envelope-tegument structures (Szil~igyi & Cunningham, 1991; McLauchlan & Rixon, 1992) . The gene 71-encoded 192K protein was found in both L particles and virions, indicating that it is a component of the envelope or tegument (Fig. 5a ). To distinguish between these two possibilities, purified virions were labelled in vitro with UDP-[HC]galactose by enzymatic labelling, to identify exposed carbohydrate residues on the virion envelope surface. Labelled proteins were analysed by SDS-PAGE (Fig. 5 b) . The position of the gene 71 polypeptide was determined by alignment with the 192K polypeptide recognized by anti-71 in immunoblotting. From these experiments we concluded that the protein product of gene 71 is a component of EHV-1 virion envelopes.
Post-translational modification of the gene 71-encoded polypeptide
The gene 71-encoded polypeptide contains a single putative N-linked glycosylation site and an extensive region encoding a high proportion of serine and threonine residues, which is likely to be heavily Oglycosylated (Telford et al., 1992 (Fig. 6c) . The apparent M r of the gene 71 polypeptide was reduced by about 9K following treatment with tunicamycin. Treatment with monensin resulted in disappearance of the high 192K M r form of the gene 71 polypeptide and an increase in the amount of an 80K M r protein band, which is the predicted primary product. Purified EHV-1 was also digested with glycanase enzymes and analysed by SDS-PAGE followed by Western blotting (Fig. 6d) . 
Immunofluorescence staining pattern of the gene 71 protein product on the surface of EHV-l-infected cells
The location of the gene 71 protein in EHV-l-infected BHK-21 (C13) cells was examined at 2 0 h p . i . by immunofluorescence using anti-71 (data not shown). The product of gene 71 was detected specifically on the surface of EHV-1-infected BHK-21 (C 13) cells.
The relationship between the gene 71 protein product and gp300 of EHV-1
It became apparent during the course of this study that the high M r glycoprotein encoded by gene 71 of EHV-1 Ab4 was very similar in size and other characteristics to gp300, a polypeptide previously identified as the product of EHV-1 gene 28 (Allen & Yeargan, 1987; Whittaker et at., 1990 Whittaker et at., , 1992 .
To resolve this discrepancy we constructed a revertant, designated Re71, in which the deletion of gene 71 in ED71 was restored. The restriction enzyme profile of Re71 was identical to that of wild-type EHV-1 (data not shown). The growth impairment shown by ED71 (Sun & Brown, 1994) had been corrected in Re71, indicating that this was due to the absence of the gene 71 polypeptide product (data not shown). We then compared the polypeptide product ofgene 71 with gp300 using EHV-1, ED71, RE71 and two antibodies, anti-71 and MAb P19, which had previously been used to characterize gp300 (Whittaker et al., 1990; Fig. 7) . Extracts from cells infected with EHV-1 (lanes 2, 6, 8 and 12), ED71 (lanes 4 and 10), Re71 (lanes 1 and 7) or mock-infected (lanes 3 and 9), and EHV-1 in the presence of tunicamycin (lanes 5 and 11) were analysed by 8 % S D S -P A G E crosslinked with either bis-acrylamide (Fig. 7a) or N,N'-diallyltartardiamide (DATD; Fig. 7 b) . Western blotting was carried out using either anti-71 (lanes 7 to 12) or MAb P19 (lanes 1 to 6). The polypeptide recognized following EHV-1 infection by both anti-71 and MAb P19 had the same electrophoretic mobility (192K). 
Discussion
EHV-1 gene 71 is located in the short unique region of the genome and is predicted to encode a 797 amino acid polypeptide with a M r of 80.1K (Telford et al., 1992) . The putative polypeptide of gene 71 possesses hydrophobic amino-and carboxy-terminal domains which may serve as a potential signal sequence and transmembrane domain respectively (Fig. 1) . It also contains a single potential N-linked glycosylation site and an extensive region encoding a high proportion of serine and threonine residues. These features suggest that the gene 71 product is a class 1 membrane glycoprotein with heavy O-linked and limited N-linked glycosylation, which is likely to result in very slow electrophoretic mobility in SDS-PAGE. The observations presented in this paper are consistent with the sequence analysis. Similar sequence features have been found in HSV-1 gC and HSV-2 gG (Serafini-Cessi et al., 1985) which are heavily O-glycosylated and have an extended region containing a high proportion of serine and threonine residues, presumed to comprise most of the O-linked glycosylation sites (McGeoch et al., , 1993 .
We have demonstrated that gene 71 encodes a 192K The immunofluorescence and virion surface labelling experiments showed that the gene 71 product is located on the surfaces of virion envelopes and infected cell membranes. It is hoped that, in conjunction with antibodies to specific domains of the protein and by electron microscopy, the precise arrangement of the gene 71 polypeptide on the virion envelope can be revealed. The transcriptional pattern of the genome of EHV-1 is similar to HSV-1 (Cohen et al., 1975; Clements et al., 1977) . On comparison with two HSV-1 genes, a true late gene (US11) and an early gene (UL42), we concluded that expression of the gene 71 polypeptide is regulated in a leaky late manner in infected cells. Among the identified EHV-1 glycoproteins (Abodeely et al., 1971; Kemp et al., 1974; Perdue et al., 1974; Turtinen & Allen, 1982; Meredith et al., 1989) , one with a M r in excess of 200K, designated either gp 1, gp2, gp 1/2 or gp300, has been identified and subsequently characterized as a heavily O-linked glycoprotein with a M,. estimated as 400K by SDS-PAGE cross-linked with DATD (Whittaker et al., 1990) . Recently, gp300 was demonstrated to be encoded by EHV-1 gene 28, using an anti-gp300 MAb, P19, and a fusion protein from part of the gene 28 ORF (Whittaker et al., 1992) . During the course of our study it became apparent that gp300 has very similar characteristics to the gene 71 polypeptide. The comparative experimental data using anti-71 and P19 presented here demonstrated that the gene 71 polypeptide and gp300 synthesized in EHV-1 Ab4-infected cells have identical electrophoretic mobilities to each other by SDS PAGE, cross-linked either with bisacrylamide or DATD in the presence or absence of tunicamycin. Also, gp300 was absent in cells infected with the mutant ED71 in which the gene 71 ORF was deleted, but was detected in cells infected with the revertant Re7I in which the gene 71 ORF had been restored. The result with Re71 ruled out the possibility of a secondary mutation in ED71 gene 28, which could have disrupted the gene. We concluded therefore that gp300 is in fact encoded by EHV-1 gene 71 and not by gene 28 as previously determined. The sequence of EHV-1 gene 28, unlike that of gene 71 (Telford et aI., 1992) , is not typical of a membrane protein; there is no apparent signal sequence (McGeoch, 1985) and there is only one region (amino acids 130 to 148) of sufficient length and hydrophobicity to be membrane spanning (Kyte & Doolittle, 1982) . Furthermore, unlike gene 71 there is no region rich in serine or threonine residues to suggest heavy O-glycosylation.
The precise stage(s) of the virus life cycle at which the gene 71 polypeptide plays a role is uncertain. Some reports about the possible functions of O-linked oligosaccharides suggest that they could play a role in polypeptides acquiring their final conformation (Gibson et al., 1980) , in increasing hydration of cells, in protecting virus from degradation or in transport of viral glycoproteins or virions to the cell surface (Johnson & Spear, 1983) . It has been suggested that if the serine-and threonine-rich region of gene 71 is heavily Oglycosylated, this region will form a highly extended semi-flexible rod of 70 nm in length on the surface of the virus particle (McGeoch et al., 1993) . The data using monensin presented in this paper confirms that gene 71 is heavily O-glycosylated and would therefore support this prediction. Interestingly, despite being released from infected BHK-21 (C13) cells, mutant ED71 virions could not be banded on 5 to 15 % Ficoll gradients (data not shown), suggesting that virions lacking gene 71 may band aberrantly.
We have previously demonstrated that the gene 71 product is dispensable for growth in tissue culture. The polypeptide gp300 has been reported to be involved in cell-cell fusion. A MAb, G12, against gp300 was found to inhibit celt~cell fusion of EHV-l-infected cells (Whittaker et al., 1992) . In agreement with this observation, ED71 causes small plaques in infected cells. Observations in vivo have shown that the mutant ED71 grows poorly in the lungs of mice and is less virulent than wild-type virus and other EHV-1 lacZ insertion mutants (K. Marshall and H. J. Field, personal communicaton). 
